| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/25/2006 | US7034109 Intracellular delivery of biological effectors |
| 04/25/2006 | US7034057 Controlling tumor necrosis factor; antiinflamamtory agents, autoimmune disease |
| 04/25/2006 | US7034056 Aryl and biaryl compounds having MCH modulatory activity |
| 04/25/2006 | US7034055 2-aminoindane analogs |
| 04/25/2006 | US7034049 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 04/25/2006 | US7034045 Monofluoroalkyl derivatives |
| 04/25/2006 | US7034044 NMDA (N-methyl-D- aspartate)-receptor subtype blockers and are used in the treatment or prevention of CNS disorders i.e. Alzheimer's, Parkinson's, etc. |
| 04/25/2006 | US7034043 Cell adhesion inhibitors |
| 04/25/2006 | US7034042 Corticotropin releasing factor receptor antagonist |
| 04/25/2006 | US7034041 Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine |
| 04/25/2006 | US7034034 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives |
| 04/25/2006 | US7034033 Substituted quinazolinone compounds |
| 04/25/2006 | US7034031 Modulators of TNF-α signaling |
| 04/25/2006 | US7034027 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers |
| 04/25/2006 | US7034025 Administering to a mammal an effective dose of a cysteine derivatives containing heteroaromatic group for the treatment of arterial tension, embryogenesis, oncogenesis, diabetes, cell proliferation, and other diseases |
| 04/25/2006 | US7034023 Antidepressants, anxiolytic agents; corticotropin releasing factor receptor antagonist |
| 04/25/2006 | US7034022 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections |
| 04/25/2006 | US7034021 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 04/25/2006 | US7034018 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 04/25/2006 | US7034017 Substituted oxazolidinones and their use in the field of blood coagulation |
| 04/25/2006 | US7034006 Use of lipid conjugates in the treatment of disease |
| 04/25/2006 | US7033995 Production of radial glial cells |
| 04/25/2006 | US7033812 β-secretase and modulation of β-secretase activity |
| 04/25/2006 | US7033779 Method for preparing steroids modified by yeast fermentation |
| 04/25/2006 | US7033770 Comprises winglesslint 8D (Wnt-8D) polypeptides for treating asthma, nervous system, psychological, alzheimer, cancer, cardiomyopathies, lung and kidney disorders; wound healing agents; tissue engineering |
| 04/25/2006 | US7033615 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 04/25/2006 | US7033575 Delivery of physiologically active compounds through an inhalation route |
| 04/25/2006 | CA2522899C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521956C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521908C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521891C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521887C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521833C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521828C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521792C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521776C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2438097C Cannabinoids pharmaceutical formulations |
| 04/25/2006 | CA2251949C Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 04/25/2006 | CA2194885C Substituted benzamidines, their preparation and their use as pharmaceutical compounds |
| 04/25/2006 | CA2189525C 2-(aminomethyl)-3,4,7,9-tetrahydro-2h-pyrano-[2,3e]indol-8-ones and derivatives |
| 04/20/2006 | WO2006042249A2 Methods and compositions for treating migraine pain |
| 04/20/2006 | WO2006041985A2 Thienopyridinone compounds and methods of treatment |
| 04/20/2006 | WO2006041975A1 Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them |
| 04/20/2006 | WO2006041405A1 Substituted amino-pyrimidones and uses thereof |
| 04/20/2006 | WO2006041404A1 Substituted amino-compounds and uses thereof |
| 04/20/2006 | WO2006041197A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ |
| 04/20/2006 | WO2006041158A1 Method for modifying the ambience, and spray liquid and sprayer used in the method |
| 04/20/2006 | WO2006041088A1 Brain disposition marrow progenitor |
| 04/20/2006 | WO2006040680A1 Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| 04/20/2006 | WO2006040451A2 Novel 9h-pyrido[2,3-b]indole derivatives serving as cdk and gsk3 inhibitors, method for the preparation thereof, and the pharmaceutical compositions containing such compounds |
| 04/20/2006 | WO2006040352A1 Novel azabicyclic aryl derivatives and their medical use |
| 04/20/2006 | WO2006040314A1 Treatment of bipolar disorders and associated symptoms |
| 04/20/2006 | WO2006040192A1 Pyrrolidine derivatives as histamine receptors ligands |
| 04/20/2006 | WO2006040182A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040180A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040179A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040178A1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040177A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 recptor |
| 04/20/2006 | WO2006040176A1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | WO2006040151A1 Subsituted hydroxyethylamine compounds for treating alzheimer’s disease |
| 04/20/2006 | WO2006040149A1 Heterocyclic ketone compounds for treating alzheimer’s disease |
| 04/20/2006 | WO2006040148A1 Tricyclic indole derivatives for use in the treatment of alzheimer’s disease |
| 04/20/2006 | WO2006040047A2 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit) |
| 04/20/2006 | WO2006040038A1 Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
| 04/20/2006 | WO2006039792A1 Method of treating autoimmune diseases |
| 04/20/2006 | WO2006020156A3 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| 04/20/2006 | WO2006018609A3 Anti-inflammatory agents |
| 04/20/2006 | WO2006016192A3 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 04/20/2006 | WO2005097183A3 Treatment of diseases |
| 04/20/2006 | WO2005063296A3 Therapeutic combination for cognition enhancement and psychotic disorders |
| 04/20/2006 | WO2005023255A3 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process |
| 04/20/2006 | US20060084809 Compounds as PDE IV and TNF-inhibitors |
| 04/20/2006 | US20060084803 Bicyclic pyridine and pyrimidine P38 kinase inhibitors |
| 04/20/2006 | US20060084699 Antagonists of the B2 receptor of bradykinin; analgesics; hyperalgesia and major algesia; cancer; nontoxic; industrial scale; 5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide |
| 04/20/2006 | US20060084693 e.g. 4-{2-[4-(5-cyano-1H-indol-3-yl)butylamino]ethoxy}benzofuran-2-carboxylic acid methyl ester; serotonin 5 HT1A and 5HT1D receptors agonist and antagonist, serotonin reuptake inhibitor; neuroleptic and hypotensive agent; |
| 04/20/2006 | US20060084688 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 04/20/2006 | US20060084677 2-sulfo, sulfanyl, sulfinyl, sulfonyl, or sulfamyl-5-substituted-6-sulfonyl quinolines; sulfiding, oxidation, dehalogenation or aralkylation of the 6-sulfonylquinoline; selective cyclooxygenase-2 inhibitors, analgesics; side effect reduction |
| 04/20/2006 | US20060084667 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 04/20/2006 | US20060084662 E.g., 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or the hydrochloride or oxalate; treating depression, anxiety disorder, and obsessive compulsive disorder. |
| 04/20/2006 | US20060084661 IL-8 receptor antagonists |
| 04/20/2006 | US20060084657 Piperazine derivative |
| 04/20/2006 | US20060084643 6-Fluoro-10-[3-(2-methoxy-ethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene; dopamine D2 and serotonin receptor anatagonist; neuroleptic agent, antidepressnt; psychological, bipolar disorders, psychosis, schizophrenia, acute mania |
| 04/20/2006 | US20060084641 IL-8 receptor antagonists |
| 04/20/2006 | US20060084613 Dipeptide enzyme inhibitor; antiinflammatory agents; autoimmune disease; wound healing agents |
| 04/20/2006 | US20060084137 Coagulation, mechanical agitation; filtration |
| 04/20/2006 | US20060084135 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 04/20/2006 | US20060084121 OX2 receptor homologs |
| 04/20/2006 | US20060083784 Amorphous pharmaceutical compositions |
| 04/20/2006 | US20060083774 Neurophilin ligands for treating ocular conditions |
| 04/20/2006 | US20060083740 By modulating the expression of mutant and wild type CD83 gene products produced in a mammal; regulation of T cell and dendritic cell activity; antibodies |
| 04/20/2006 | US20060083676 For marking and identifying metabotropic glutamate receptor sites and for imaging an organ; in particular non-competitive mGlu1 receptor ligands |
| 04/20/2006 | DE102004050196A1 Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Substituted 2-pyridone derivatives, processes for their preparation and their use as a medicament |
| 04/20/2006 | DE102004048927A1 Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren A pharmaceutical combination comprising deoxypeganine and Cyp2D6 inhibitors |
| 04/20/2006 | DE102004048716A1 Verwendung von Lavendelöl zur Prophylaxe und Behandlung von Neurasthenie, Somatisierungsstörungen und von anderen stress-assoziierten Erkrankungen The use of lavender oil for the prophylaxis and treatment of neurasthenia, somatization disorders and other stress-related diseases |
| 04/20/2006 | CA2584836A1 Novel azabicyclic aryl derivatives and their medical use |
| 04/20/2006 | CA2583983A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583973A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583967A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583918A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583353A1 Thienopyridinone compounds and methods of treatment |